Cystine-Targeted Liposomes for Hyperproliferative Cell Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current chemotherapeutic drugs for hyperproliferative disorders face limitations due to nonspecific toxicity, inefficient drug delivery, and inappropriate drug release, leading to low therapeutic indexes and significant side effects.
Innovation Solution
Development of pharmaceutical compositions that utilize cystine molecules to target the System x_c- heterodimeric amino acid transporter in hyperproliferative cells, facilitating the targeted intracellular delivery of therapeutic and diagnostic agents via liposome-encapsulated nanoparticles.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If chemotherapeutic drugs are administered to treat hyperproliferative disorders, then therapeutic effect is achieved, but nonspecific toxicity to normal tissues occurs
Solution Approach 1:
The patent segments the drug delivery system into distinct components: a targeting moiety (cystine or anti-System xc- antibody) that specifically binds to tumor cells, and the therapeutic cargo (chemotherapeutic agent) enclosed within a delivery vehicle (liposome or nanoparticle). This segmentation allows the therapeutic effect to be concentrated at the target site while minimizing exposure to normal tissues, thereby resolving the contradiction between therapeutic efficacy and nonspecific toxicity.
Solution Approach 2:
The patent introduces an intermediary targeting molecule (cystine or anti-System xc- antibody) that mediates the interaction between the drug delivery vehicle and the tumor cell surface. This intermediary specifically recognizes and binds to the System xc- transporter, which is overexpressed on tumor cells, enabling selective drug delivery to the target cells while sparing normal tissues from toxic effects.
2Reliability
If high doses of chemotherapeutic drugs are administered to overcome low therapeutic index, then therapeutic efficacy improves, but side effects increase
Solution Approach 1:
The patent segments the drug delivery system into a targeting component and a therapeutic cargo component, allowing the drug to be delivered selectively to tumor cells. This segmentation enables the use of higher therapeutic doses to achieve better efficacy while the targeting mechanism ensures that the increased dose is concentrated at the tumor site rather than distributed systemically, thereby reducing side effects.
Solution Approach 2:
The patent implements local quality by endowing the drug delivery vehicle with site-specific targeting capability through the incorporation of cystine or anti-System xc- antibody moieties. This allows the high dose of chemotherapeutic agent to be delivered locally to the tumor tissue with high concentration at the target site, while normal tissues receive minimal exposure, thus achieving improved efficacy without proportional increase in side effects.
3Ease of operation
If conventional drug delivery systems are used, then drug administration is simple, but drug delivery efficiency to target cells is low
Solution Approach 1:
The patent creates a multi-functional drug delivery system where a single vehicle (liposome or nanoparticle) performs multiple functions: (1) encapsulation and protection of the therapeutic cargo, (2) active targeting to tumor cells via cystine or anti-System xc- antibody moieties, and (3) potential passive targeting through EPR effect. This universal platform maintains relative ease of administration while dramatically improving drug delivery efficiency to target cells compared to conventional simple administration.
Solution Approach 2:
The patent introduces an intermediary targeting moiety (cystine or anti-System xc- antibody) that mediates between the drug delivery vehicle and the tumor cell surface receptor. This intermediary enables specific recognition and binding to System xc- transporters on tumor cells, significantly enhancing drug delivery efficiency to the target cells while maintaining a relatively simple administration route through intravenous injection.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enhances the delivery of therapeutic agents to hyperproliferative cells, reducing side effects and increasing efficacy by exploiting the increased expression of System x_c- components in tumor cells, thereby improving treatment outcomes for hyperproliferative diseases.
Implementation Method 1
the cystine component of the vehicle interacts with the transporter to initiate a series of cellular events that cause the target cell to endocytose the vehicle
Implementation Method 2
cause the target cell to endocytose the vehicle or various components of the vehicle, e.g., a therapeutic or diagnostic agent
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The invention provides pharmaceutical compositions containing a vehicle for the targeted delivery of therapeutic and diagnostic agents for the treatment of hyperproliferative diseases. The targeting component of the vehicle is a cystine molecule that is coupled to the cargo component, which can be either a therapeutic or diagnostic agent or to a nanoparticle composition that contains the therapeutic agent or diagnostic. The invention also provides methods of treating hyperproliferative disorders by targeting hyperproliferative disease cells for the targeted delivery of a therapeutic or diagnostic agent.